Le Lézard
Classified in: Health, Science and technology
Subjects: PLW, MAT

MMJ International Holdings Files US Patent Prior To FDA Study For Cannabinoid Treatment Medicine



RESTON, Va., Jan. 3, 2018 /PRNewswire-PRWeb/ -- MMJ International Holdings, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research and the operation of medical cannabis healthcare businesses, today announced that it has filed another patent invention with the United States Patent and Trademark Office that relates to pharmaceutical compounds and methods for treating and/or preventing symptoms associated with cannabinoid responsive diseases and disorders, such as Multiple Sclerosis (MS), and Huntington's disease (HD).

MMJ BioScience's disclosed invention generally relates to pharmaceutical compounds and methods for treating and/or preventing diseases and disorders that often manifest in hyper and/or hypokinetic movements symptoms, as well as the method of administering therapeutically-effective amounts of a pharmaceutical compound containing cannabinoids to Multiple Sclerosis (MS) and Huntington's (HD) disease patients in need of treatment. The disclosed invention further relates to cannabinoid pharmaceutical compounds where said compound contains at least some non-cannabinoid components.The MMJ BioScience has filed these patents to protect the delivery of its MMJ BioScience® product formulation for its upcoming multiple sclerosis FDA study which is progressing through the Federal Drug Administrations (FDA) regulatory process.

Dr. Bianca Weinstock-Guttman, MMJ BioScience's principal investigator, is a Professor of Neurology at the State University of New York at Buffalo who serves as Executive Director of the New York State Multiple Sclerosis Consortium. Dr. Weinstock-Guttman will oversee the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients.

In late 2017 MMJ BioScience had submitted an application with the United States Food and Drug Administration (FDA) for approval of a new pharmaceutical drug. Unlike other cannabis-type medicines, MMJ BioScience's medicine is plant derived. When approval is received from the FDA the new medicine would be on sale across America as an approved drug.

MMJ BioScience's expected approval by the FDA for its new medicine would have a major impact on the state to state emerging cannabis industry which is not federally legal. Most recently the FDA had issued several cease and desist letters to firms that are marketing unapproved cannabinoid products. Whereas non-pharmaceutical companies cannot export their products across state lines, MMJ BioScience would be able to sell its medicine in pharmacies once prescribed by physicians.

MMJ BioScience's discovery of a novel cannabinoid pharmacology through our network of world leading scientists, our intellectual property portfolio, proprietary formulations, processing, and regulatory expertise uniquely position us to develop and manufacture plant-derived cannabinoid formulations at sufficient quality and uniformity according to the FDA regulatory requirements for pharmaceutical development.

 

SOURCE MMJ International Holdings


These press releases may also interest you

at 17:35
Helix BioPharma Corp. , a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2019 ending October 31, 2018. FINANCIAL...

at 17:21
CGI executives rang The Closing Bell® today at the New York Stock Exchange, marking 20 years as an NYSE listed company. Over the period since 1998, CGI has increased its employee base by nearly ten-fold, increased its revenue by more than 15 times...

at 17:14
Intrinsic4D Inc. (the "Company") (NEX:IFD.H) announces its intention to proceed with a consolidation of its issued and outstanding voting common shares, subject to receipt of shareholder approval at a special meeting of shareholders to be held on...

at 16:41
TE Connectivity Ltd. , a world leader in connectivity and sensors, announced today that its board of directors has authorized an increase in its share repurchase program by an additional $1.5 billion. Any repurchases by the company will be made in...

at 16:12
TymeMachine is excited to host the first Community Coding Competition for students between the ages of 8 and 18, sponsored by Ladue Education Foundation & Alumni Association. Codefest 2019 will take place March 30th, 2019...

at 16:08
Linxup by Agilis Systems, a leading provider of GPS fleet management tools and asset trackers, has partnered with Fleetio to provide automatic mileage tracking for fleet maintenance management. Fleetio's preventative...




News published on 3 january 2018 at 13:00 and distributed by: